Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Medical Genetics

Navigating Labs and Diagnostic Tests

At a Glance

OTC deficiency is diagnosed using a combination of biochemical tests and genetic sequencing. High plasma ammonia and elevated urine orotic acid are the primary biochemical markers. Because standard newborn screening often misses OTC deficiency, targeted blood, urine, and genetic tests are crucial.

Diagnosing Ornithine Transcarbamylase (OTC) deficiency is like solving a puzzle with two types of pieces: biochemical (how the body is functioning right now) and genetic (the underlying blueprint) [1][2]. Because symptoms can look like many other illnesses, knowing which labs to check—and when to check them—is vital for an accurate diagnosis.

The Newborn Screening Gap

It is important to know that OTC deficiency is frequently missed on standard state newborn screening (NBS) panels [1]. These screens typically flag urea cycle disorders by detecting high levels of citrulline. However, because OTC deficiency results in low citrulline, it can easily evade detection [3]. If a newborn is severely ill, normal NBS results should never be used to completely rule out OTC deficiency [1].

The Biochemical “Fingerprint”

When the body cannot process nitrogen correctly, it leaves behind a specific pattern in the blood and urine.

  • Plasma Ammonia: This is the most urgent test. Ammonia is a toxic waste product that should be converted into urea. High levels (hyperammonemia) indicate the waste disposal system is failing [4][5].
    • Patient Tip: Ammonia levels can rise and fall quickly. Testing is most accurate during an acute crisis (when the patient feels sick) [6].
  • Urine Orotic Acid: This is the “hallmark” of OTC deficiency. When the OTC enzyme isn’t working, the body creates an excess of orotic acid, which spills into the urine [3]. This test is essential because it helps doctors tell the difference between OTC and other similar disorders [4].
  • Plasma Citrulline: Citrulline is a product the urea cycle normally makes. In OTC deficiency, citrulline levels are typically very low or at the low end of the normal range [4]. While important, citrulline levels alone aren’t enough to confirm a diagnosis [3].

Confirming the Genetic Blueprint

Once the biochemical tests suggest OTC deficiency, genetic testing is used to find the specific mutation in the OTC gene [7]. A complete genetic audit should include:

  1. Gene Sequencing: This “reads” the gene letter-by-letter to look for spelling errors (mutations) [8].
  2. MLPA (Multiplex Ligation-dependent Probe Amplification): Standard sequencing can miss large “chunks” of missing or extra genetic material. MLPA is a specialized test that looks for these larger deletions or duplications [7][9].
  3. Specialized Testing: If standard tests are negative but symptoms are classic, doctors may look for deep-intronic variants (mutations hidden in the non-coding parts of the gene) or use advanced tools like hiPSC technology (using stem cell technology to grow and study your liver cells in a lab) to see how they process ammonia [10][11].

Diagnostic Checklist

If you are auditing your or your child’s medical records, ensure these steps were completed:

  • [ ] Ammonia Level: Was it high (usually >100 μmol/L in newborns or >50 μmol/L in adults)? [12]
  • [ ] Urine Orotic Acid: Was it elevated? (This is the most specific biochemical marker for OTC) [3].
  • [ ] Amino Acid Profile: Does it show low citrulline and high glutamine? [13].
  • [ ] Genetic Confirmation: Was a full OTC gene panel performed, including MLPA? [14].
Marker Typical Result in OTC Deficiency Why it Matters
Ammonia High Shows immediate toxicity risk to the brain [15].
Orotic Acid High Distinguishes OTC from other urea cycle defects [4].
Citrulline Low Indicates the urea cycle “relay race” has stopped early [4].
Glutamine High Another waste product that rises when ammonia is high [13].

Common questions in this guide

Why might standard newborn screening miss OTC deficiency?
Newborn screening typically looks for high citrulline levels to flag urea cycle disorders. Because OTC deficiency causes low citrulline levels, it is frequently missed on these standard state panels.
What does high urine orotic acid mean for OTC deficiency?
Elevated urine orotic acid is a hallmark sign of OTC deficiency. When the OTC enzyme isn't working properly, the body produces excess orotic acid, which helps doctors distinguish OTC deficiency from other similar metabolic disorders.
Why is plasma ammonia testing important during an acute illness?
Ammonia is a toxic waste product that can build up when the body's nitrogen disposal system fails. High ammonia levels indicate a dangerous buildup that can pose immediate risks to the brain, requiring urgent evaluation and management.
What genetic tests are used to confirm OTC deficiency?
Doctors typically start with gene sequencing to look for small mutations or 'spelling errors' in the OTC gene. If that is negative, they use a specialized test called MLPA to look for larger missing or extra chunks of genetic material.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Were the ammonia and amino acid samples drawn while I/my child was actively symptomatic?
  2. 2.Since the initial sequencing was negative, can we perform MLPA testing to look for large deletions or duplications?
  3. 3.If genetic testing remains unclear, is testing for 'deep-intronic' variants an option?
  4. 4.Can you explain the difference between the 'orotic acid' level and the 'citrulline' level in this specific report?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Maternal and Newborn Care for Ornithine Transcarbamylase Deficiency.

    Anderson S

    MCN. The American journal of maternal child nursing 2025; (50(1)):46-51 doi:10.1097/NMC.0000000000001057.

    PMID: 39623541
  2. 2

    [Consensus on diagnosis and treatment of ornithine trans-carbamylase deficiency].

    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2020; (49(5)):539-547 doi:10.3785/j.issn.1008-9292.2020.04.11.

    PMID: 33210478
  3. 3

    Clinical and molecular characteristics of 69 Chinese patients with ornithine transcarbamylase deficiency.

    Lu D, Han F, Qiu W, et al.

    Orphanet journal of rare diseases 2020; (15(1)):340 doi:10.1186/s13023-020-01606-2.

    PMID: 33272297
  4. 4

    The role of orotic acid measurement in routine newborn screening for urea cycle disorders.

    Staretz-Chacham O, Daas S, Ulanovsky I, et al.

    Journal of inherited metabolic disease 2021; (44(3)):606-617 doi:10.1002/jimd.12331.

    PMID: 33190319
  5. 5

    Case Report: Juvenile Myelomonocytic Leukemia Underlying Ornithine Transcarbamylase Deficiency Safely Treated Using Hematopoietic Stem Cell Transplantation.

    Eguchi H, Kakiuchi T, Nishi M, et al.

    Frontiers in pediatrics 2022; (10()):898531 doi:10.3389/fped.2022.898531.

    PMID: 35601422
  6. 6

    Adult-onset diagnosis of urea cycle disorders: Results of a French cohort of 71 patients.

    Toquet S, Spodenkiewicz M, Douillard C, et al.

    Journal of inherited metabolic disease 2021; (44(5)):1199-1214 doi:10.1002/jimd.12403.

    PMID: 34014557
  7. 7

    Clinical and Genetic Analysis of 8 Children With Ornithine Transcarbamylase Deficiency: Two Novel Mutations.

    Zhang C, Shan J, Su J, et al.

    Neurology. Genetics 2024; (10(6)):e200204 doi:10.1212/NXG.0000000000200204.

    PMID: 39559585
  8. 8

    Variant analysis and PGT-M of OTC gene in a Chinese family with ornithine carbamoyltransferase deficiency.

    Zhou Y, Jiang X, Zhang Y, et al.

    BMC pregnancy and childbirth 2024; (24(1)):491 doi:10.1186/s12884-024-06696-5.

    PMID: 39039447
  9. 9

    [Applying multiplex ligation-dependent probe amplification in the diagnosis of 5 cases with ornithine transcarbamylase deficiency].

    Gong ZW, Han LS, Ye J, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2016; (54(6)):437-40 doi:10.3760/cma.j.issn.0578-1310.2016.06.010.

    PMID: 27256231
  10. 10

    A deep intronic variant is a common cause of OTC deficiency in individuals with previously negative genetic testing.

    Kumar RD, Burrage LC, Bartos J, et al.

    Molecular genetics and metabolism reports 2021; (26()):100706 doi:10.1016/j.ymgmr.2020.100706.

    PMID: 33489762
  11. 11

    Induced pluripotent stem cell technology as diagnostic tool in patients with suspected ornithine transcarbamylase deficiency lacking genetic confirmation.

    Ramosaj A, Singhal P, Schaller A, Laemmle A

    Molecular genetics and metabolism reports 2023; (37()):101007 doi:10.1016/j.ymgmr.2023.101007.

    PMID: 38053928
  12. 12

    Fatal coma in a young adult due to late-onset urea cycle deficiency presenting with a prolonged seizure: a case report.

    Alameri M, Shakra M, Alsaadi T

    Journal of medical case reports 2015; (9()):267 doi:10.1186/s13256-015-0741-2.

    PMID: 26593089
  13. 13

    A preliminary retrospective evaluation of screening and diagnosis of ornithine transcarbamylase deficiency in high-risk patients at a referral center in Vietnam.

    Tran DM, Tran TTT, Luong QH, Tran MTC

    Heliyon 2024; (10(16)):e36003 doi:10.1016/j.heliyon.2024.e36003.

    PMID: 39220945
  14. 14

    Ornithine transcarbamylase deficiency: A diagnostic odyssey.

    Knerr I, Cassiman D

    Journal of inherited metabolic disease 2022; (45(4)):661-662 doi:10.1002/jimd.12530.

    PMID: 35734906
  15. 15

    Severe Sepsis Associated With Multiorgan Failure and Precipitating Nonhepatic Hyperammonemia Crisis in Late-Onset Ornithine Transcarbamylase Deficiency: A Case Report and Literature Review.

    Forsah SF, Ugwendum D, Arrey Agbor DB, et al.

    Cureus 2024; (16(3)):e55711 doi:10.7759/cureus.55711.

    PMID: 38586796

This page explains diagnostic tests for OTC deficiency for educational purposes only. Always consult your medical geneticist or metabolic specialist for accurate interpretation of your specific lab and genetic results.

Get notified when new evidence is published on Ornithine transcarbamylase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.